Amgen Ventures has come on board as an investor in genomics services platform Wuxi NextCode, in a round co-led by Temasek and Yunfeng Capital.
US-based genomics services provider Wuxi NextCode has raised $75m in a series B round featuring Amgen Ventures, the corporate venturing arm of biopharmaceutical company Amgen.
The round was co-led by Singapore government-owned investment firm Temasek and private equity firm Yunfeng Capital, and also featured private equity firm 3W Partners.
Wuxi NextCode operates a contract genomics platform that offers features such as sequencing, secondary analysis, storage, interpretation and scalable analytics.
The company was founded as NextCode Health in 2013 but was…
